COSMOS Pharmaceutical Corporation (3349.T)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Forecast and Price Target with Analyst Ratings, Revenue Estimates, and complete financial and advanced discounted cashflow forecasts for up to 10 years.

Trending:

COSMOS Pharmaceutical Corporation (3349.T) Stock Forecast & Price Prediction | Analyst Ratings

Revenue

726.42B

Lower than competitor

Worse than 3141.T's revenue of 949.65B.

Revenue Growth Rate

6.14%

Higher than competitor

Better than 3141.T's revenue growth rate of 0.00%.

EBITDA

46.93B

Lower than competitor

Worse than 3141.T's ebitda of 59.95B.

EBITDA Margin

6.46%

Higher than competitor

Better than 3141.T's ebitda margin of 6.31%.

EBIT

33.15B

Lower than competitor

Worse than 3141.T's ebit of 42.98B.

EBIT Margin

4.56%

Higher than competitor

Better than 3141.T's ebit margin of 4.53%.

Depreciation

13.79B

Lower than competitor

Better than 3141.T's depreciation of 16.98B.

Total Cash

55.11B

Higher than competitor

Better than 3141.T's total cash of 51.92B.

Cash as Percentage of Revenue

7.59%

Higher than competitor

Better than 3141.T's cash as percentage of revenue of 5.47%.

Receivables

100.00M

Lower than competitor

Better than 3141.T's receivables of 44.82B.

Receivables as Percentage of Revenue

0.01%

Lower than competitor

Better than 3141.T's receivables as percentage of revenue of 4.72%.

Inventories

60.55B

Lower than competitor

Better than 3141.T's inventories of 103.28B.

Inventories as Percentage of Revenue

8.34%

Lower than competitor

Better than 3141.T's inventories as percentage of revenue of 10.88%.

Accounts Payable

133.04B

Lower than competitor

Better than 3141.T's accounts payable of 150.39B.

Payables as Percentage of Revenue

18.31%

Higher than competitor

Worse than 3141.T's payables as percentage of revenue of 15.84%.

Capital Expenditure

-26.06B

Lower than competitor

Better than 3141.T's capital expenditure of -14.46B.

CapEx as Percentage of Revenue

-3.59%

Lower than competitor

Better than 3141.T's capex as percentage of revenue of -1.52%.

Weighted Average Cost of Capital (WACC)

5.07%

Higher than competitor

Worse than 3141.T's weighted average cost of capital (wacc) of 4.64%.

Cost of Equity

5.18%

Higher than competitor

Worse than 3141.T's cost of equity of 4.93%.

Cost of Debt

3.99%

Equal to 3141.T's cost of debt of 3.99%.

Beta

0.25

Higher than competitor

Worse than 3141.T's beta of 0.16.

Diluted Shares Outstanding

79.24M

Lower than competitor

Better than 3141.T's diluted shares outstanding of 207.25M.

Total Debt

34.06B

Lower than competitor

Better than 3141.T's total debt of 81.25B.

Total Equity

696.60B

Higher than competitor

Better than 3141.T's total equity of 533.45B.

Total Capital

730.66B

Higher than competitor

Better than 3141.T's total capital of 614.70B.

Debt Weighting

4.66%

Lower than competitor

Better than 3141.T's debt weighting of 13.22%.

Equity Weighting

95.34%

Higher than competitor

Better than 3141.T's equity weighting of 86.78%.

EBIAT

23.32B

Lower than competitor

Worse than 3141.T's ebiat of 29.13B.

Unlevered Free Cash Flow

571.10M

Lower than competitor

Worse than 3141.T's unlevered free cash flow of 33.93B.

Long-Term Growth Rate

2.00%

Equal to 3141.T's long-term growth rate of 2.00%.

Terminal Value

379.47B

Lower than competitor

Worse than 3141.T's terminal value of 1.90T.

Enterprise Value

352.82B

Lower than competitor

Worse than 3141.T's enterprise value of 1.71T.

Net Debt

-18.24B

Lower than competitor

Better than 3141.T's net debt of 46.24B.

Equity Value

371.06B

Lower than competitor

Worse than 3141.T's equity value of 1.67T.

Equity Value Per Share

4682.70

Lower than competitor

Worse than 3141.T's equity value per share of 8040.13.

Select Metric for Chart